Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Oil Prices Rise Amid Iran Conflict and Strait of Hormuz Disruption 
Iran-U.S. Conflict Escalation Threatens Global Oil Supply and Economic Stability 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Wall Street Mixed as Apple Earnings Boost Nasdaq and Oil Prices Ease 
US Stock Futures Rise as S&P 500 and Nasdaq Hit Record Highs Amid Earnings Optimism and Iran Tensions 
Trump Rejects Iran Proposal as Tensions Persist Amid Fragile Ceasefire 
EU Warns of Response as U.S. Considers 25% Tariffs on Car Imports 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Wall Street Surges to Record Highs Amid Strong Earnings and Economic Stability 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
China Factory Activity Extends Growth in April Despite Global Pressures 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
AI Stocks Rally in Asia as Oil Surge and Hawkish Central Banks Shake Global Markets 
Abbott Nutrition said last weekend that it had reopened its Sturgis, Michigan plant to resume the production of baby formula. The company hopes that the nationwide shortage of milk will be addressed once it begins the normal production once again.
Abbott Nutrition was able to open its production facility in Michigan after the U.S. Food and Drug Administration (USFDA) had given it the go-ahead to do so. The permit was granted by the agency after the company met the initial requirements as part of a May 16 consent decree.
According to CNBC, Abbott Nutrition will now restart the production of its EleCare baby formula that has been formulated for children who have difficulties digesting other products. The company will also manufacture its other specialty milk and metabolic formulas for infants.
As the company is now able to begin production again, it is hoping to release the first batch of EleCare milk products by June 20. Currently, Abbott is still working to comply with the guidelines set for the resumption of production for its Similac milk line and other infant formulas.
“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” Abbott’s spokesman said in a statement. “We will ramp production as quickly as we can while meeting all requirements.“
It was noted that the issue with the supply of baby formula began in the early stage of the COVID-19 pandemic. However, the situation got worse when Abbott Nutrition’s production facility in Michigan was ordered to close due to contamination. The plant was shut down in February following reports of illnesses in babies after consuming the company-made milk formulas, and two infants have died.
“The FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan, facility,” the USFDA commented with regards to Abbot’s plant reopening. “The agency expects that the measures and steps it is taking, and the potential for Abbott Nutrition’s Sturgis, Michigan, facility, to safely resume production in the near-term, will mean more and more infant formula is either on the way to or already on store shelves moving forward.”
